1. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
- Author
-
Borthwick AD, Davies DE, Ertl PF, Exall AM, Haley TM, Hart GJ, Jackson DL, Parry NR, Patikis A, Trivedi N, Weingarten GG, and Woolven JM
- Subjects
- Animals, Antiviral Agents blood, Biological Availability, Brain metabolism, Cells, Cultured, Dogs, Drug Design, Enzyme-Linked Immunosorbent Assay, Eye metabolism, Ganciclovir pharmacology, Guinea Pigs, Half-Life, Humans, Indicators and Reagents, Kinetics, Mass Spectrometry, Models, Molecular, Protease Inhibitors blood, Structure-Activity Relationship, Substrate Specificity, Antiviral Agents chemical synthesis, Antiviral Agents pharmacology, Cytomegalovirus drug effects, Cytomegalovirus enzymology, Lactams chemical synthesis, Lactams pharmacology, Protease Inhibitors chemical synthesis, Protease Inhibitors pharmacology, Pyrroles chemical synthesis, Pyrroles pharmacology, Serine Endopeptidases metabolism
- Abstract
A series of chiral, (S)-proline-alpha-methylpyrrolidine-5,5-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivatives of para-substituted phenyl ureas > para-substituted phenyl sulfonamides > para-substituted phenyl carboxamide for activity against HCMV deltaAla protease, producing para-substituted phenyl ureas with single figure nM potency (K(i)) against the viral enzyme. The SAR of the functionality on the lactam nitrogen has defined the steric and electronic requirements for high human plasma stability while retaining good activity against HCMV protease. The combination of high potency against HCMV deltaAla protease and high human plasma stability has produced compounds with significant in vitro antiviral activity against human cytomegalovirus with the 6-hydroxymethyl benzothiazole derivative 72 being equivalent in potency to ganciclovir. The parent benzothiazole 56 had good pharmacokinetics in dogs with 29% bioavailability and good brain and ocular penetration in guinea pigs.
- Published
- 2003
- Full Text
- View/download PDF